Reducing Complement Inhibition to Treat Leukemia and Lymphoma

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43CA162582-01
Agency Tracking Number: R43CA162582
Amount: $300,000.00
Phase: Phase I
Program: SBIR
Awards Year: 2011
Solicitation Year: 2011
Solicitation Topic Code: NCI
Solicitation Number: PA10-050
Small Business Information
1102 COLUMBIA ST, STE 110, SEATTLE, WA, 98104-
DUNS: 831167734
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 DARRICK CARTER
 (206) 623-0331
 darrick.carter@complimentcorp.com
Business Contact
 DARRICK CARTER
Phone: (206) 714-2724
Email: darrick.carter@complimentcorp.com
Research Institution
 Stub
Abstract
DESCRIPTION (provided by applicant): The funding of the application will yield safety and efficacy data on a new combination cancer therapy for leukemia and lymphomas. Monoclonal antibodies (mAbs) have emerged as a class of novel oncology therapeutics. Weare developing a molecule that can improve the therapeutic effects of mAbs by: 1) increasing the sensitivity of cancers to treatment 2) unmasking resistant cancers so they again become sensitized and 3) potentially allowing treatment of cancers that havebecome refractory to therapy. This project will move a clinical candidate forward for future testing in humans. The public health implications of dose-sparing and cost reduction for mAb therapy, improved outcomes in cancer and making a new therapy available for previously resistant cancers are significant. The immediate goal of the research is to collect data to enable an Investigational New Drug (IND) filing on a combination therapy for lymphoma. Our consultant at the University of Washington has collecteda significant body of information supporting the superiority of the combination of depleting CD46 on the cell surface with antibody therapy in blood cancers Our long-term goal is to translate the technology from research bench to clinical bedside leadingto enhancement of monoclonal antibody (mAb) therapy. PUBLIC HEALTH RELEVANCE: Although monoclonal antibody therapy can be an effective way to treat cancer, further progress is needed to increase therapeutic success. We intend to enhance cancer therapy to improve treatment worldwide.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government